US Patent

US10426782 — Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation

Formulation · Assigned to Millennium Pharmaceuticals Inc · Expires 2035-06-23 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing Compound 1 or a salt thereof for treating cancer and a process for its preparation.

USPTO Abstract

The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.

Drugs covered by this patent

Patent Metadata

Patent number
US10426782
Jurisdiction
US
Classification
Formulation
Expires
2035-06-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Millennium Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.